SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 0

Recent Reports in Diabetes

Diyabette Son Çalışmalar

Sema ORUÇ DÜNDAR
Harun ÇAKMAK
Pages
75–80
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this re- view; latest clinical research for the anti-VEGF agents, steroids and laser used in clinical practice are summarized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are many reports on the treatment patterns for diabetic macular edema and proliferative diabetic retinopathy.
📊
Key Findings & Data:There are many reports on the treatment patterns for diabetic macular edema and proliferative diabetic retinopathy.
💡
Conclusion & Impact:In this re- view; latest clinical research for the anti-VEGF agents, steroids and laser used in clinical practice are summarized.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There are many reports on the treatment patterns for diabetic macular edema and proliferative diabetic retinopathy. In this re- view; latest clinical research for the anti-VEGF agents, steroids and laser used in clinical practice are summarized.

Özet

Diyabetik makula ödemi ve proliferatif diyabetik retinopati teda- visi ile ilgili çok sayıda çalışma mevcuttur. Bu derlemede günü- müzde kullanılmakta olan anti VEGF ajanlar, steroidler ve laser ile ilgili güncel klinik araştırmalar özetlenmiştir.

🔖

Cite This Article

DÜNDAR, S. O., ÇAKMAK, H. (2017). Recent Reports in Diabetes. Retina-Vitreus, Cilt: 26 - Sayı: 0, 75–80. https://ajindex.com/articles/304883

References (10)

  1. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, et al. Afl ibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193–203.
  2. Wells JA, Glassman AR, Ayala AR ve ark. Afl ibercept, Be- vacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Eff ectiveness Rando- mized Clinical Trial. Ophthalmology. 2016;123(6):1351-9
  3. Jampol LM, Glassman AR, Bressler NM ve ark. Anti-Vas- cular Endothelial Growth Factor Comparative Eff ectiveness Trial for Diabetic Macular Edema: Additional Eff icacy Post Hoc Analyses of a Randomized Clinical Trial JAMA Opht- halmol. 2016;134(12):doi:10.1001/jamaophthalmol.2016.3698 Heier JS, Korobelnik JF, Brown DM ve ark. Intravitre- al Afl ibercept for Diabetic Macular Edema 148-Week Re- sults from the VISTA and VIVID Studies; Ophthalmology 2016;123(11):2376-85.
  4. Wykoff CC, Le RT, Khurana RN ve ark. Outcomes with As-Needed Afl ibercept and Macular Laser Following the Pha- se III VISTA DME Trial: ENDURANCE 12-Month Extension Study. Am J Ophthalmol. 2017;173:56-63.
  5. Bressler SB, Glassman AR, Almukhtar T ve ark. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab forDiabetic Macular Edema. American Journal of Ophthal- mology, 2016;164:57-68.
  6. Patrao NV, Antao S, Egan C ve ark. Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting. American Journal of Ophthalmology 2016;172:51-57.
  7. Pieramici DJ, Wang P, Ding B ve ark. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Li- mited Initial Anatomic Response to Ranibizumab in RIDE and RISE. Ophthalmology 2016;123(6):1345-1350.
  8. Callanan DG, Loewenstein A, Patel SS ve ark. A multicenter, 12-month randomized study comparing dexamethasone int- ravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol (2016). doi:10.1007/s00417-016-3472-1
  9. Malcles A, Dot C, Voirin N ve ark. Safety of Intravitreal Dexa- methasone Implant (Ozurdex). The SAFODEX Study. Incı- dence and Risk Factor of Ocular Hypertension. Retina 2016; doi: 10.1097/IAE.0000000000001369 Elaraoud I, Andreatta W, Kidess A ve ark. Use of fl ucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmology (2016) 16:3:1-5
  10. Chen G, Tzekov R, Li W ve ark. Subtreshold